

# ***In vivo* ligation of glucocorticoid-induced TNF receptor enhances the T-cell immunity to herpes simplex virus type 1**

Soojin La<sup>1</sup>, Eunhwa Kim<sup>1</sup> and  
Byung Suk Kwon<sup>1,2</sup>

<sup>1</sup>The Immunomodulation Research Center and  
Department of Biological Science  
University of Ulsan  
Ulsan 680-749, Korea

<sup>2</sup>Corresponding author: Tel, 82-52-259-2860;  
Fax, 82-52-259-2740; E-mail, bkwn@mail.ulsan.ac.kr

Accepted 6 May 2005

Abbreviations: DLN, draining lymph node; gB, glycoprotein B; gD, glycoprotein D; GITR, glucocorticoid-induced tumor necrosis factor receptor; GVHD, graft-versus-host disease; HSV-1, herpes simplex virus type 1

## **Abstract**

**GITR (glucocorticoid-induced TNF receptor) is a recently identified member of the TNF receptor superfamily. The receptor is preferentially expressed on CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells and GITR signals break the suppressive activity of the subset. In this study, we wanted to reveal the *in vivo* function of GITR in herpes simplex virus type 1 (HSV-1) infection. A single injection of anti-GITR mAb (DTA-1) immediately after viral infection significantly increased the number of CD4<sup>+</sup> and CD8<sup>+</sup> T cells expressing CD25, an activation surface marker, and secreting IFN- $\gamma$ . We confirmed these *in vivo* observations by showing *ex vivo* that re-stimulation of CD4<sup>+</sup> or CD8<sup>+</sup> T cells with a CD4<sup>+</sup> or CD8<sup>+</sup> T-cell-specific HSV-1 peptide, respectively, induced a significant elevation in cell proliferation and in IFN- $\gamma$  secretion. Our results indicate that GITR signals play a critical role in the T-cell immunity to HSV-1.**

**Keywords:** GITR; HSV-1; gB; gD; Th1 cell; CTL

## **Introduction**

GITR (glucocorticoid-induced TNF receptor) was originally identified by comparing untreated and dexamethasone-treated murine T-cell hybridoma cells (Nocentini *et al.*, 1997). Later, human orthologue and

its ligand were cloned by searching an EST (expressed sequence tag) database (Gurney *et al.*, 1999; Kwon *et al.*, 1999a; 1999b; 2003). GITR expression is up-regulated on T cells after activation, and a high level of GITR is constitutively expressed on CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells (McHugh *et al.*, 2002; Shimizu *et al.*, 2002). Initial characterization of GITR functions revealed that the receptor could inhibit T-cell receptor (TCR)-induced apoptosis in the T cell hybridoma that was used to clone the GITR gene (Nocentini *et al.*, 1997). This was confirmed in a human T cell line (Gurney *et al.*, 1999). Consistently, GITR-deficient mouse T cells exhibited a higher capacity to proliferate in response to TCR stimulation but underwent higher levels of activation-induced cell death (Ronchetti *et al.*, 2002). In CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells, GITR signals have been shown to abrogate their suppressive function (McHugh *et al.*, 2002; Shimizu *et al.*, 2002). However, recent studies have demonstrated that GITR functions as a costimulatory molecule for conventional T cells *in vitro* (Ji *et al.*, 2004; Kanamaru *et al.*, 2004; Kohm *et al.*, 2004; Muriglan *et al.*, 2004; Ronchetti *et al.*, 2004) and that GITR-deficient mouse CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells were able to exert the suppressive activity on conventional CD4<sup>+</sup> T cells as equally as wild-type CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells (Ronchetti *et al.*, 2002).

The *in vivo* function of GITR remains largely to be defined. In this study, we wanted to reveal the *in vivo* function of GITR in an HSV-1 infection model. Our data demonstrated that ligation of GITR markedly increased the T-cell immunity to HSV-1.

## **Materials and Methods**

### **Mice and peptides**

Female Balb/c mice, 6-8 wk of age, were purchased from Orient (Seoul, Korea). The HSV-1 glycoprotein D<sub>246-261</sub> (gD<sub>246-261</sub>: APYTSTLLPPELSETP) peptide was described previously (Grammer *et al.*, 1990) and was shown to be specific for Th1 cells (BenMohamed *et al.*, 2003). The gB<sub>498-505</sub> (SSIEFARL) peptide is an immunodominant peptide for CD8<sup>+</sup> T cells (Hanke *et al.*, Witmer *et al.*, 1990; Bonneau *et al.*, 1993). The peptides were synthesized by Peptron (Daegen, Korea).

### **mAbs and flow cytometry**

Anti-GITR mAb (DTA-1) was described previously (Shimizu *et al.*, 2002) and purified from ascites. Control rat Ig was purchased from Sigma (St Louis, MO). FITC-anti-CD3, FITC- or phycoerythrin (PE)-anti-

CD4, FITC- or PE-anti-CD8, PE-anti-CD25, and PE-anti-IFN- $\gamma$  mAbs were purchased from BD Biosciences Pharmingen (San Diego, CA). Lymphocytes were stained and analyzed as described previously (Kim *et al.*, 2005). Intracellular staining for IFN- $\gamma$  was performed according to the manufacturer's instruction (BD Biosciences Pharmingen).

### Virus and infection

The KOS strain of HSV-1 was used in this study. For the production of the virus stock supernatant, the virus-infected Vero cell cultures were centrifuged at 1,500 rpm and filtered with a 0.45- $\mu$ m mesh filter to remove cellular debris. The viruses were titrated using the end-point dilution method. Balb/c mice were inoculated with  $5 \times 10^5$  PFU of HSV-1 injected s.c. into each hind footpad. DTA-1 or control Ig (300  $\mu$ g per mouse) was i.p. injected immediately thereafter.

### Proliferation assay


The DLNs were harvested from HSV-1-infected mice and a single cell suspension was prepared in PBS. The cell debris was removed by passing through 70- $\mu$ m cell strainer (BD Falcon, San Diego, CA). Isolated lymphocytes ( $5 \times 10^5$ ) were cultured at various concentrations of peptide for 72 h. Proliferation was assessed in triplicate by pulsing with 1 Ci [ $^3$ H]thymidine for 12 h.

### ELISA

IFN- $\gamma$  was measured from culture supernatant, using an ELISA kit (Endogen, Woburn, MA), according to the manufacturer's protocol.

### Statistical analysis

Student *t* test was used to determine the statistical significance of differences between experimental groups.



**Figure 1.** Ligation of GTR activates CD4<sup>+</sup> T cells after HSV-1 infection. Mice were infected in the hind footpad with  $5 \times 10^5$  PFU of HSV-1. DTA-1 or control Ig (300  $\mu$ g per mouse) was i.p. injected immediately thereafter. (A) The number of total lymphocytes isolated from the DLN. (B) CD4<sup>+</sup> T cells derived from the DLN were counted by staining the DLN cells with anti-CD3 and anti-CD4. (C) Activated CD4<sup>+</sup> T cells were counted by staining the DLN cells with anti-CD4 and anti-CD25. (D) The DLN cells were stained for CD4 combined with intracellular staining for IFN- $\gamma$ . Data are shown as mean  $\pm$  SD of *n* = 3. \**P* < 0.05, between the 2 groups at the indicated time points.


## Results and Discussion

Agonistic anti-GITR antibody (DTA-1) has been shown to abolish the immunosuppressive activity of  $CD4^+$   $CD25^+$  regulatory T cells (Shimizu *et al.*, 2002). Administration of DTA-1 exacerbates experimental autoimmune encephalomyelitis (Kohm *et al.*, 2004) and acute graft-versus-host disease (GVHD) (Muriglian *et al.*, 2004). Using this agonistic mAb, we examined its effect on the immune response to HSV-1 infection. The kinetics for the expansion of total lymphocytes and  $CD4^+$  T cells was similar in the DLN of DTA-1- and control Ig-treated mice at all the time points investigated except for 5-day postinfection (Figure 1A and B). We next counted activated  $CD4^+$  T cells by analyzing the expression of CD25 on the cell surface of  $CD4^+$  T cells and by staining intracellular IFN- $\gamma$  that represents effector T cells more precisely. Both methods showed that a noticeable expansion of activated  $CD4^+$  T cells from DTA-1-treated mice began at 5-day postinfection and reached a peak at day 7 (Figure 1C and D). In comparison with control Ig-treated mice, marked increase in activated  $CD4^+$  T-cell numbers was observed in DTA-1-treated mice between day 5 and day 9 after infection (Figure 1C and D). Although activated  $CD4^+$  T cells expressing CD25 existed in the


DLN of control Ig-treated mice, production of intracellular IFN- $\gamma$  in  $CD4^+$  T cells was barely detectable (Figure 1D). Our results indicate that DTA-1 potentially induced the expansion of effector  $CD4^+$  T cells to viral antigens.

Unlike  $CD4^+$  T cells,  $CD8^+$  T-cell numbers were significantly greater between day 5 and day 9 in the DLN of DTA-1-treated mice compared with those of control Ig-treated mice (Figure 2A). At day 14, the number of both  $CD4^+$  and  $CD8^+$  T cells of DTA-1-treated mice was significantly reduced, presumably as a result of activation-induced death (Figure 1A and 2A). The kinetics of activated  $CD8^+$  T-cell expansion was parallel to that of activated  $CD4^+$  T-cell expansion (Figure 2C and D). We did not detect activation of  $CD4^+$  and  $CD8^+$  T cells in non-draining lymph nodes in either group after HSV-1 infection (data not shown). Taken together, our results suggest that *in vivo* ligation of GITR can significantly increase activation of both  $CD4^+$  and  $CD8^+$  T cells after HSV-1 infection.

To directly verify whether ligation of GITR induces the generation of antigen-specific T cells, the DLN-derived T-cell responses to peptide epitopes were examined *ex vivo* 7 days after infection. Our results showed that the Th1-specific gD<sub>246-261</sub> peptide vigo-



**Figure 2.** Ligation of GITR activates  $CD8^+$  T cells after HSV-1 infection. Mice were infected in the hind footpad with  $5 \times 10^5$  PFU of HSV-1. DTA-1 or control Ig (300  $\mu$ g per mouse) was i.p. injected immediately thereafter. (A)  $CD8^+$  T cells isolated from the DLN were counted by staining the DLN cells with anti-CD3 and anti-CD8. (C) Activated  $CD8^+$  T cells were counted by staining the DLN cells with anti-CD8 and anti-CD25. (D) The DLN cells were stained for CD8 combined with intracellular staining for IFN- $\gamma$ . Data are shown as mean  $\pm$  SD of  $n = 3$ . \* $P < 0.05$ , between the 2 groups at the indicated time points.




**Figure 3.** Increase in gD<sub>246-261</sub>-specific T cells. (A) The cells isolated from the DLN at 7-day postinfection were stimulated with various concentrations of gD<sub>246-261</sub> peptide for 72 h. Proliferation was assessed in triplicate by pulsing with 1 Ci [<sup>3</sup>H]thymidine for the last 12 h. (B) After the DLN cells were stimulated with 10 μg of gD<sub>246-261</sub> peptide for 24 h, supernatants were collected and assayed for IFN-γ by ELISA. (C) The DLN cells were stimulated with 10 μg of gD<sub>246-261</sub> peptide for 6 h and were stained for CD4 combined with intracellular staining for IFN-γ. \**P* < 0.05, between the 2 groups.

rously stimulated the proliferation of T cells from DTA-1-treated mice in a dosage-dependent manner (Figure 3A). In our experimental conditions, T cells of control Ig-treated mice had a minimal proliferation. In consistence, peptide-stimulated T cells of DTA-1-treated mice secreted high levels of IFN-γ compared with those of control Ig-treated mice (Figure 3B). Intracellular IFN-γ staining analysis demonstrated that DTA-1-treated mice had approximately 30-fold increase in the frequency of gD<sub>246-261</sub> peptide-specific CD4<sup>+</sup> T cells as compared with control Ig-treated mice (Figure 3C). Similarly, the CD8<sup>+</sup> T cell-specific gB<sub>498-505</sub> peptide induced such a vigorous *in vitro* response as the gD<sub>246-261</sub> peptide did (Figure 4). These data indicate that *in vivo* GTR stimulation can augment the expansion of antigen-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells after HSV-1 infection.

The expression pattern of GTR suggests that GTR may be involved in functions of a variety of immune cells, including T cells, B cells and macrophages (Shimizu *et al.*, 2002). In agreement of our

data presented in this report, results from other *in vivo* studies have shown that GTR stimulation increases Th1 autoreactivity in experimental autoimmune encephalomyelitis (Kohm *et al.*, 2004) and CD8<sup>+</sup> T cell-mediated acute GVHD (Muriglan *et al.*, 2004). Ligation of GTR also has been shown to markedly enhance the CD8<sup>+</sup> T-cell activity in chronic GVHD (manuscript in submission). It is possible that several mechanisms of action underlying the *in vivo* observations are operative; GTR signals either activate the CD4<sup>+</sup> and CD8<sup>+</sup> T cells through depressing the immunosuppressive activity of CD4<sup>+</sup>CD25<sup>+</sup> T cells (Kohm *et al.*, 2004) or directly activate CD25<sup>+</sup>CD4<sup>+</sup> or CD25<sup>+</sup>CD8<sup>+</sup> conventional T cells (Muriglan *et al.*, 2004; manuscript in submission). In a chronic GVHD that is mediated by Th2 cells, *in vivo* engagement of GTR prevents donor CD8<sup>+</sup> T-cell tolerance and the subsequent activation of donor CD8<sup>+</sup> T cells and Th1 CD4<sup>+</sup> T cells shifts chronic GVHD toward acute GVHD (manuscript in submission).

The main finding presented in this report is to



**Figure 4.** Increase in gB<sub>498-505</sub>-specific T cells. (A) The cells isolated from the DLN at 7-day postinfection were stimulated with various concentrations of gB<sub>498-505</sub> peptide for 72 h. Proliferation was assessed in triplicate by pulsing with 1 Ci [<sup>3</sup>H]thymidine for the last 12 h. (B) After the DLN cells were stimulated with 10 μg of gB<sub>498-505</sub> peptide for 24 h, supernatants were collected and assayed for IFN-γ by ELISA. (C) The draining lymph node cells were stimulated with 10 μg of gB<sub>498-505</sub> peptide for 6 h and were stained for CD8 combined with intracellular staining for IFN-γ. \**P* < 0.05, between the 2 groups.

reveal *in vivo* the involvement of a GITR co-stimulatory pathway in viral infection. To be equally important, we provide a possibility of GITR stimulation as an adjuvant in elevating the immune response to efficiently remove viral infection. Our results demonstrated that ligation of GITR induced approximately 30-fold and 80-fold increase in the frequency of antigen-specific CD4<sup>+</sup> Th1 cells and CD8<sup>+</sup> T cells, respectively (Figure 3 and 4). It seems that *in vivo* ligation of GITR removes HSV-1 viruses from the infection site rapidly (our preliminary data). Since the T-cell response takes an action against viruses 5-7 days after infection, the rapid kinetics for the viral removal indicates that GITR signals may be important for anti-viral activities mediated by other cells (e.g., macrophages, dendritic cells, NK cells, and residential cells in the infection site) than T cells. Therefore, this adjuvant effect of anti-GITR mAb may be critical in removing viruses by triggering the innate immunity. In sum, our data suggest a possibility that *in vivo* ligation of GITR may be effective in removing the primary

viral infection.

#### Acknowledgement

This work was supported by grants from University of Ulsan (2003-0087) and the SRC Fund to the IRC from KOSEF and the Korean Ministry of Science and Technology.

#### References

- BenMohamed LB, Bertrand G, McNamara CD, Gras-Masse H, Hammer J, Wechsler SL, Nesburn AB. Identification of novel immunodominant CD4<sup>+</sup> Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. *J Virol* 2003;77:9463-73
- Bonneau RA, Salvucci LA, Johnson DC, Tevethia SS. Epitope specificity of H-2K<sup>b</sup>-restricted, HSV-1-, and HSV-2-cross-reactive cytotoxic T lymphocyte clones. *Virology* 1993;

195:62-70

Grammer SF, Sette A, Colon S, Walker L, Chesnut R. Identification of an HSV-1/HSV-2 cross-reactive T cell determinant. *J Immunol* 1990;145:2249-53

Gurney AL, Masters SA, Huang A, Huang RM, Mark M, Baldwin DT, Gray AM, Dowd P, Bush PJ, Helden S, Schow P, Goddard AD, Wood WI, Baker KP, Godowski PJ, Ashkenazi A. Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. *Curr Biol* 1999;9:215-18

Hanke T, Graham FL, Reosenthal KL, Johnson DC. Identification of an immunodominant cytotoxic T-lymphocyte recognition site in glycoprotein B of herpes simplex virus by using recombinant adenovirus vectors and synthetic peptides. *J Virol* 1991;65:1177-86

Ji H-b, Liao G, Faubion WA, Abadia-Molina AC, Cozzo C, Laroux FS, Canton A, Terhoshorst C. Cutting edge: The natural ligand for glucocorticoid-induced TNF-related protein abrogates regulatory T cell suppression. *J Immunol* 2004;172:4686-90

Kanamaru F, Youngnak P, Hashiguchi M, Nishioka T, Takahashi T, Sakaguchi S, Isikawa I, Azuma M. Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25<sup>+</sup> regulatory CD4<sup>+</sup> T cells. *J Immunol* 2004;172:7306-14

Kim J, Choi WS, La S, Suh J-H, Kim B-S, Cho HR, Kwon BS, Kwon B. Stimulation with 4-1BB (CD137) inhibits chronic graft-versus-host disease by inducing activation-induced cell death of donor CD4<sup>+</sup> T cells. *Blood* 2005;105:2206-13

Kohm AP, Williams JS, Miller SD. Cutting edge: Ligation of the glucocorticoid-induced TNF receptor enhances autoreactive CD4<sup>+</sup> T cell activation and experimental autoimmune encephalomyelitis. *J Immunol* 2004;172:4686-90

Kwon B, Yu KY, Ni J, Yu GL, Jang IK, Kim YJ, Xing L, Liu D, Wang SX, Kwon BS. Identification of a novel activation-induced protein of the tumor necrosis factor receptor superfamily and its ligand. *J Biol Chem* 1999a;274:6056-61

Kwon B, Youn B-S, Kwon BS. Functions of newly identified

members of the tumor necrosis factor receptor/ligand super-families in lymphocytes. *Curr Opin Immunol* 1999b;10:340-5

Kwon B, Kim B-S, Cho HR, Park J-E, Kwon BS. Involvement of tumor necrosis factor receptor superfamily (TNFRSF) members in the pathogenesis of inflammatory diseases. *Exp Mol Med* 2003;35:8-16

McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M, Byrne MC. CD4<sup>+</sup>CD25<sup>+</sup> immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid TNF receptor. *Immunity* 2002;16:311-23

Muriglian SJ, Ramirez-Montagut T, Alpdogan O, van Huystee TW, Eng JM, Hubbard VM, Kochman AA, Tjoe KH, Riccardi C, Pandolfi PP, Sakaguchi S, Houghton AN, van den Brink VRM. GITR activation induces an opposite effect on allo-reactive CD4<sup>+</sup> and CD8<sup>+</sup> T cells in graft-versus-host disease. *J Exp Med* 2004;200:149-57

Nocentini G, Giunchi L, Rochetti S, Krusz LT, Bartoli A, Moraca R, Migliorati G, Riccardi CA. A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. *Proc Natl Acad Sci USA* 1999;94:6216-21

Ronchetti S, Nocentini G, Riccardi C, Pandolfi PP. Role of GITR in activation response of T lymphocytes. *Blood* 2002;100:350-2

Ronchetti S, Zollo O, Bruscoli S, Agostini M, Bianchini R, Nocentini G, Ayroldi E, Riccardi C. Frontline: GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulation. *Eur J Immunol* 2004;34:613-22

Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25<sup>+</sup>CD4<sup>+</sup> regulatory T cells through GITR breaks immunological self-tolerance. *Nat Immunol* 2002;3:135-42

Witmer LA, Rosenthal KL, Graham FL, Friedman HM, Yee A, Johnson DC. Cytotoxic T lymphocytes specific for herpes simplex virus (HSV) studied using adenovirus vectors expressing HSV glycoproteins. *J Gen Virol* 1990;71:387-96